



Q 3634: Dr. Srinivasan is a senior scientist working for a reputed biotechnology company known for its cutting-edge research in pharmaceuticals. Dr. Srinivasan is heading a research team working on a new drug aimed at treating a rapidly spreading variant of a new

You must Purchase the required course for access.

viral infectious disease. The disease has been rapidly spreading

across the world and the cases reported in the country are

Password:

Enter

increasing. There is huge pressure on Dr. Srinivasan's team to

expedite the trials for the drug as there is significant market for it,

and the company wants to get the first-mover advantage in the

market. During a team meeting, some senior team members suggest

some shortcut for expediting the clinical trials for the drug and for

getting the requisite approvals. These include manipulating data to

exclude some negative outcomes and selectively reporting positive

results, foregoing the process of informed consent and using

compounds already patented by a rival company, rather than

developing one's own component. Dr. Srinivasan is not comfortable

taking such shortcuts, at the same time he realises meeting the

targets is impossible without using these means.